Mallinckrodt shakes up pharma world with $925m deal – Therakos’ new era begins!
Mallinckrodt plc, a prominent global specialty pharmaceutical firm, has announced a major deal with CVC Capital Partners, one of the world’s leading investment firms. Under the newly signed definitive agreement, CVC Capital Partners Fund IX will acquire Mallinckrodt’s Therakos business for approximately $925 million, subject to customary adjustments. The sale marks a significant move for […]